EHA 2018 | Common misconceptions around MRD for MM prognosis
Bruno Paiva
• 14 Jun 2018
Measurable residual disease (MRD) is used as a prognostic indictor in a variety of hematological maliganancies, including multiple myeloma (MM). We asked Bruno Paiva, PhD, of the University of Navarra, Navarra, Spain, about common misconceptions amongst clinicians when it comes to using MRD as a prognostic marker for MM at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Dr Paiva discusses why patients are often misclassified as MRD-negative, as well as why MRD status should be treated as a simple biomarker that is complemented by other information.
